Seeking Alpha

Of all the company's which have managed to generate a large cult like following, perhaps no micro-cap stock has done as good of a job as the .07 cent stem cell company Advanced Cell Technology (OTCQB:ACTC). Since the company's inception in the mid 90's as an animal cloning company, Advanced Cell Technology has managed to dilute its current number of outstanding shares to a whopping 2,560,000,000 since its original IPO. Needless to say, it has not been a profitable ride for long-term shareholders thus far. Rather, it appears that shareholders have been hit time and time again with dilutions, and questionable actions by management, which whether purposeful or accidental, has not reflected well on the company. Interestingly enough...

Only subscribers can access this article, which is part of the PRO research library covering 3,741 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: